| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amgen Inc. | ABP 959 - (SOLIRIS biosimilar) | Paroxysmal nocturnal hemoglobinuria (PNH) | Phase 3 | Intravenous | Hematology | |
| Amgen Inc. | Rocatinlimab (AMG 451/KHK4083) - (ROCKET/IGNITE) | Moderate to severe atopic dermatitis (AD) | Phase 3 | Data Released | Intravenous | Immunology |
| Amgen Inc. | KHK4083/AMG 451 - (ROCKET) | Atopic dermatitis | Phase 3 | Intravenous | Immunology | |
| Amgen Inc. | Tezepelumab - (WAYPOINT) | Chronic Rhinosinusitis With Nasal Polyps | Phase 3 | Data Released | Subcutaneous | Respiratory |
| Amgen Inc. | ABP 654 - (STELARA biosimilar) | Plaque psoriasis | Phase 3 | Ongoing | Subcutaneous | Immunology: Anti-TNF |
| Amgen Inc. | Tezepelumab | Eosinophilic esophagitis (EoE) | Phase 3 | Ongoing | Subcutaneous | Gastroenterology |
| Amgen Inc. | Rocatinlimab - (ASCEND) | Moderate to severe atopic dermatitis (AD) | Phase 3 | Data Released | Subcutaneous | Immunology |
| Amgen Inc. | ABP 654 - (STELARA biosimilar) | Plaque psoriasis | Phase 3 | Ongoing | Subcutaneous | Immunology: Anti-TNF |